Capecitabine for Recurrent Ovarian Cancer
Author Information
Author(s): Vasey P A, McMahon L, Paul J, Reed N, Kaye S B
Primary Institution: Beatson Oncology Centre, Western Infirmary, Glasgow, UK
Hypothesis
Can capecitabine be an effective treatment for patients with recurrent ovarian cancer?
Conclusion
Capecitabine showed a response rate of 29% in patients with previously treated ovarian cancer and had a manageable safety profile.
Supporting Evidence
- Capecitabine resulted in a response rate of 29% in a population of 28 evaluable patients.
- Median progression-free survival was 3.7 months and overall survival was 8.0 months.
- Capecitabine was well tolerated with manageable side effects.
Takeaway
This study tested a pill called capecitabine for women with ovarian cancer that came back after treatment, and it helped some of them feel better.
Methodology
This was an open-label, phase II trial assessing the efficacy and safety of capecitabine in women with platinum-pretreated epithelial ovarian cancer.
Potential Biases
Potential bias due to the open-label design and lack of randomization.
Limitations
The small sample size and the lack of a control group limit the generalizability of the findings.
Participant Demographics
{"median_age":57,"age_range":"38-78","performance_status":{"0":8,"1":17,"2":1,"unknown":3},"disease_stage_at_diagnosis":{"Ic":1,"II":1,"III":17,"IV":10},"prior_chemotherapy":{"1_course":4,"2_courses":13,">2_courses":12}}
Statistical Information
P-Value
0.47
Confidence Interval
{"response_rate":"95% CI, 13–49%","progression_free_survival":"95% CI, 2.8–4.6","overall_survival":"95% CI, 4.1–11.8"}
Statistical Significance
p=0.47
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website